Skip to main content
Clinical Trials/NCT02471066
NCT02471066
Completed
Not Applicable

Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) on Functional Psychogenic Movement Disorders Followed by a Feasibility Study of a Hypnotherapy Treatment as Adjuvant Therapy.

University Hospital, Toulouse1 site in 1 country18 target enrollmentApril 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Movement Disorders
Sponsor
University Hospital, Toulouse
Enrollment
18
Locations
1
Primary Endpoint
Changes of Psychogenic Movement Disorder Rating Scale (PMDRS= Hinson score between baseline and one month after rTMS treatment
Status
Completed
Last Updated
5 years ago

Overview

Brief Summary

The management of functional psychogenic movement disorders (FNPMD) is challenging for neurologists and psychiatrists and only comprehensive multidisciplinary treatment programme can be worthwhile for these patients (Moene et al 2002). Recent functional magnetic resonance imaging studies have demonstrated abnormalities in motor control at cortical level, hyperactivity of limbic system and disturbance of connectivity between these two systems leading to a lack of self-agency, (Voon et al 2010,2011).Two recent studies suggested a possible therapeutic effect of transcranial magnetic stimulation (TMS) in FNPMD (Dakotakis 2011, Garcin, 2013).

In this protocol our objectives are twofold :

  1. to compare the effect of 5 consecutive daily sessions of rTMS on FNPMD in a double-blind randomized controlled study
  2. to study the effect of 3 weekly hypnosis sessions combined with rTMS in FNPMD
Registry
clinicaltrials.gov
Start Date
April 2015
End Date
January 2018
Last Updated
5 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Changes of Psychogenic Movement Disorder Rating Scale (PMDRS= Hinson score between baseline and one month after rTMS treatment

Time Frame: Inclusion and 1 month later

Secondary Outcomes

  • Pain scale (VAS)(: inclusion, inclusion + 5 days, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.)
  • Clinical Global Impression-Severity scale (CGI-SEVERITY/CGI-I/CGI-S)(inclusion, inclusion + 5 days, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.)
  • Hospital Anxiety and Depression Scale (HAD/HDRS)(inclusion, inclusion + 1 month, inclusion + 6 months, inclusion + 12 months.)
  • Quality of Life (SF-36)(inclusion, inclusion + 1 month, inclusion + 2 months, inclusion + 6 months, inclusion + 12 months.)
  • Temperament and Character Inventory (TCI)(inclusion, inclusion + 12 months.)

Study Sites (1)

Loading locations...

Similar Trials